(CERE)

業務介紹

賽瑞維爾治療控股公司(Cerevel Therapeutics Holdings, Inc.)是一家處於臨床階段的生物製藥公司,從事開發各種神經科學疾病的療法。該公司正在開發emraclidine,這是一種正性致敏調節劑(PAM),正處於1b期臨床試驗階段,用於治療精神分裂症;Darigabat也是一種PAM,正處於2期概念驗證試驗階段,用於治療藥物抗藥性局發性發作性癲癇或局灶性癲癇,同時也在1期試驗中用於治療急性焦慮。該公司的產品還包括:Tavapadon,一種選擇性多巴胺D1/D5部分激動劑,正處於3期臨床試驗階段,用於治療早期和晚期帕金森氏病;CVL-871,一種選擇性多巴胺D1/D5部分激動劑,正處於2a期臨床試驗階段,用於治療與癡呆相關的冷淡;CVL-936,一種選擇性多巴胺D3優先拮抗劑,正處於1期臨床試驗階段,用於治療物質使用障礙;CVL-354,一種選擇性kappa-opioid受體拮抗劑,用於治療重度抑鬱障礙和物質使用障礙;CVL-047,一種選擇性PDE4抑制劑,用於治療重度抑鬱障礙和物質使用障礙。該公司還參與開發一個M4激動劑項目,用於治療精神病和相關適應症,以及一個LRRK2抑制劑項目,以解決帕金森氏病的疾病進展。該公司成立於2018年,總部位於麻薩諸塞州劍橋。



Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.cerevel.com